Eupraxia Pharmaceuticals (NASDAQ:EPRX) Sees Strong Trading Volume – Here’s Why

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) saw strong trading volume on Friday . 3,055,170 shares traded hands during mid-day trading, an increase of 996% from the previous session’s volume of 278,730 shares.The stock last traded at $8.01 and had previously closed at $7.50.

Analyst Ratings Changes

A number of brokerages have commented on EPRX. Oppenheimer began coverage on Eupraxia Pharmaceuticals in a research note on Thursday, June 25th. They set an “outperform” rating and a $17.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, July 15th. Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Zacks Research upgraded shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 7th. Finally, Stifel Nicolaus initiated coverage on Eupraxia Pharmaceuticals in a report on Thursday, May 21st. They set a “buy” rating and a $25.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $18.00.

Eupraxia Pharmaceuticals Stock Up 6.7%

The firm has a 50-day moving average of $6.64 and a two-hundred day moving average of $6.99. The firm has a market cap of $520.49 million, a price-to-earnings ratio of -7.82 and a beta of 1.07. The company has a current ratio of 16.00, a quick ratio of 16.00 and a debt-to-equity ratio of 0.02.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. As a group, sell-side analysts predict that Eupraxia Pharmaceuticals Inc. will post -0.87 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Royal Bank of Canada boosted its holdings in shares of Eupraxia Pharmaceuticals by 21.1% during the 1st quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock worth $1,125,000 after buying an additional 59,683 shares during the period. JPMorgan Chase & Co. increased its position in Eupraxia Pharmaceuticals by 593.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after purchasing an additional 16,017 shares during the period. Bank of America Corp DE grew its stake in Eupraxia Pharmaceuticals by 402.4% during the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after purchasing an additional 10,059 shares during the period. UBS Group AG boosted its position in shares of Eupraxia Pharmaceuticals by 155.4% during the 3rd quarter. UBS Group AG now owns 95,756 shares of the company’s stock worth $565,000 after purchasing an additional 58,257 shares in the last quarter. Finally, Raymond James Financial Inc. grew its position in Eupraxia Pharmaceuticals by 173.3% in the 3rd quarter. Raymond James Financial Inc. now owns 33,373 shares of the company’s stock valued at $197,000 after purchasing an additional 21,161 shares during the period.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.